
We’re looking for a Research Associate In Silico to join our Oxford-based Bioinformatics Team.
Bring your scientific mindset, analytical skills, and attention to detail to help drive cancer target discovery. If you’re enthusiastic about research, self-motivated, and keen to learn new techniques, we’d love to hear from you.
About Oxford Biotherapeutics
Oxford BioTherapeutics (OBT) is a clinical-stage biotechnology company developing antibody therapeutics for the treatment of cancer. You will play an integral role in the pre-clinical development of novel immuno-oncology therapeutics. Our OGAP® platform is the world's largest, cancer specific, membrane protein library, directly measuring plasma membrane protein expression in patient tumors. OGAP is used to identify novel, highly tumor specific antigens for novel first-in-class ADC, Bispecific T-cell Engager (BITE®) and Chimeric Antigen Receptor (CAR) targets. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. Our clinical and pre-clinical pipeline of novel biologics is balanced between internal programs, focused on ADCs and checkpoint regulators, and externally partnered programs with key innovators in oncology such as Roche, Boehringer Ingelheim and Zymeworks.
For further information, please check our website www.oxfordbiotherapeutics.com
Purpose of the Role
In this role, you will support the discovery, investigation, and presentation of therapeutic cancer targets using bioinformatics-based approaches. Training will be provided as needed. This position would be ideal for a bioinformatics graduate with an interest in cancer biology and/or mass spectrometry-based proteomics.
Essential Duties and Responsibilities:
Please note the roles and responsibilities for the position include but are not limited to the above.
Knowledge, Experience, and Skills:
One of our top priorities is to maintain the health and wellbeing of our employees and their families. To achieve this goal, we offer comprehensive benefits:
· Private health care (Bupa)
· Health Cash Plan
· Generous pension scheme with potential employer contribution of up to 10% (based on match contributions)
· Discretionary Annual bonus scheme
· Free onsite parking
· Office snacks
· Enhanced holiday entitlement above statutory minimum plus public holidays
· Employee Referral Bonus Program
· Annual training budget for professional development
· New hire share options
· Team building events and activities
Equal Opportunities Statement
OBT is an equal opportunity employer and prohibits unlawful discrimination based on race, colour, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status, and veteran status. All qualified applicants will receive consideration for employment.
Why Join Us
We promote a culture of innovation, responsibility, and commitment to our goals and objectives. Together, we believe, we can pool our resources and our uniqueness to develop novel, robust cures for one of the most challenging health conditions today. We recognize that our team is only as good as the people in it. Our people have used the words friendly, collaborative, and hard working to describe the culture here at OBT. This is why, while we strive to ensure that we hire only the best people. We also strive to provide a working environment that is based on cooperation, innovation, and mutual respect.
Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics.
Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly.
OBT’s proprietary OGAP® target discovery platform is based on one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe.
The company’s pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim, ImmunoGen and Kite Pharma as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS), Alere (Abbott)).
Take the next step in your career journey